Phio Pharmaceuticals (NASDAQ:PHIO) Stock: Insider Ronald Todd Plott Acquires 18,300 Shares

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Plott acquired 18,300 shares of Phio Pharmaceuticals stock in a transaction on Monday, November 9th. The stock was purchased at an average price of $0.83 per share, with a total value of $15,189.00. Following the transaction, the director directly owned 60,300 shares in the company, valued at approximately $50,049. This trade represents a 43.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ronald Todd Plott also recently made the following trade(s):

• On Monday, September 28th, Ronald Plott acquired 5,000 shares of Phio Pharmaceuticals stock. The shares were purchased at an average cost of $1.03 per share, for a total transaction of $5,150.00.
• On Wednesday, August 19th, Ronald Plott acquired 15,000 shares of Phio Pharmaceuticals stock. The shares were purchased at an average price of $1.14 per share, for a total transaction of $17,100.00.

Phio Pharmaceuticals Stock Performance

Shares of NASDAQ PHIO opened at $0.81 on Thursday. The business has a fifty day simple moving average of $0.95 and a 200 day simple moving average of $1.08. Phio Pharmaceuticals Corp. has a one year low of $0.75 and a one year high of $1.88.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). Analysts predict that Phio Pharmaceuticals Corp. will post -1.47 earnings per share for the current year.

Analysts Set New Price Targets

PHIO has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reissued a “buy” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Phio Pharmaceuticals has a consensus rating of “Hold” and an average price target of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.